Pharmaceutical Companies in Brazil: What the Register Shows About Manufacturers

Brazil's Pharmaceutical Manufacturing Sector, by the Register

Brazil is the largest pharmaceutical market in Latin America and one of the largest in the world. Industry analysis from PharmaBoardroom valued the market at roughly USD 62 billion in 2024, serving a population of more than 200 million through the public Unified Health System (SUS). With numbers like that, you might expect tens of thousands of pharmaceutical companies on the national register. The reality, when you filter precisely, is far narrower.

OneFirmIntel tracks 1,002 active pharmaceutical manufacturers on record in Brazil. Of these, 898 are graded Established (★★), 100 are Active (★), and just 4 are Listed (★★★). A further 1,684 are inactive on record, meaning they appear in the register but are dissolved, struck off, or otherwise no longer trading. That inactive tail is larger than the active population, which is a useful reminder that a raw register dump overstates the live market by a wide margin.

Why is the active count around a thousand rather than the tens of thousands the market size might imply? Because this figure captures pharmaceutical manufacturers specifically. Our industry filter maps to a narrow NACE manufacturing class for the production of pharmaceutical preparations, not to wholesalers, distributors, pharmacies, importers, clinics, or the much broader health and life-sciences sector. Brazil's medicine economy employs hundreds of thousands of people across distribution and retail, but the set of entities that actually make finished drugs and formulations is small and concentrated. When you see our count next to a market-size headline, the gap is the distribution and services layer, not missing data.

Trade Context: Volumes, Deals and News

Brazil is a powerful consumer market and a comparatively modest producer of pharmaceutical inputs, which shapes everything about how the sector trades. Domestic companies are significant: PharmaBoardroom reported that Brazilian firms accounted for around 51 percent of market turnover in 2023, while multinationals lead in value of higher-priced and innovative products. Generics are central to volume, with ANVISA-cited figures putting generics at a large share of units sold and a majority of total sales, and most generics produced domestically.

The dependence sits upstream. Brazil imports the vast majority of the active pharmaceutical ingredients (APIs) used in local production. DatamarNews reported in 2024 that Brazil imports roughly 95 percent of the APIs used to make medicines domestically, a sharp reversal from decades ago when the country produced more of its own raw materials. That input gap drives a structural trade deficit: Statista data referenced in trade coverage put Brazil's pharmaceutical trade deficit at close to USD 10 billion in 2023, with imports near USD 11 billion. Major suppliers of APIs and finished drugs include India, China, the European Union, and the United States. On the EU side specifically, Eurostat reported that medicinal and pharmaceutical products were the most-exported EU goods to Mercosur, at about EUR 6.8 billion, underlining how much of Brazil's pipeline arrives from abroad.

Policy is actively trying to close that gap. Brazil's Productive Development Partnerships (PDPs), the long-running mechanism for transferring manufacturing technology from private firms to government-owned producers for SUS-strategic drugs, were overhauled in 2024. On 20 June 2024 the Ministry of Health published Ordinances 4,472/2024 and 4,473/2024, reformulating the PDP rules and introducing a new public-private model, the Program of Local Development and Innovation (PDIL), per analysis published on the Kluwer Patent Blog. Recent dealmaking shows the direction of travel: in August 2025, Agencia Brasil reported that Fiocruz and the Brazilian company EMS signed agreements to produce the GLP-1 weight-loss agonists semaglutide and liraglutide domestically, with technology transfer to Fiocruz's Farmanguinhos unit. On the regulatory side, ANVISA issued RDC 875 in June 2024 to modernise biological-product registration, including a path to waive certain comparative clinical studies for well-characterised biosimilars, and GaBI tracking has recorded roughly 30 biosimilars approved in Brazil to date.

Sub-Sectors and Manufacturing Hubs

The manufacturer population splits into a few recognisable groups. Generics producers dominate by volume and are largely Brazilian-owned, supplying both private pharmacies and SUS tenders. Branded and innovative-drug makers include the large domestic players and the local arms of multinationals, which carry more of the market's value. A third, smaller group works on biologicals and biosimilars, an area Brazil has prioritised for local capacity. Sitting beneath all of them is the input layer: the country has relatively few API synthesis plants, which is precisely why the PDP and PDIL programmes exist.

Geographically, the sector clusters in the southeast. Sao Paulo is the unmistakable hub, home to Sindusfarma, the pharmaceutical-industry syndicate for the state of Sao Paulo, founded in 1933 and today representing a large majority of the medicines marketed in Brazil across its membership of roughly 312 companies. Research-oriented and multinational firms are organised through Interfarma, founded in 1990. Beyond Sao Paulo, Goias has grown into a major generics-manufacturing base, and Pernambuco anchors public-sector and biotech capacity in the northeast. You can see the live count and tier split for Brazilian drug manufacturers, and filter by state and registration status, in the Brazil pharmaceutical company directory.

Using OneFirmIntel Data to Source and Verify Brazilian Pharma Companies

For a buyer or analyst, the value of this dataset is that it turns a 256-million-company register population into a working shortlist. Start with the tier filter. The four Listed (★★★) manufacturers are exchange-listed and subject to continuous disclosure, so their filings are the easiest to interrogate. The 898 Established (★★) companies are privately held but show sustained filing history and operational longevity, which is usually where a serious supplier search should concentrate. The 100 Active (★) entities are real and not struck off but carry a thinner compliance footprint, so they warrant extra diligence. Skipping the 1,684 inactive records up front saves you from chasing companies that no longer trade.

Register data answers the first procurement question, is this company real and how substantial is it, but it does not confirm that a plant can legally sell a given product. That is where the ANVISA cross-check comes in. Any company manufacturing or importing medicines in Brazil must hold the relevant ANVISA authorisations and product registrations, and ANVISA inspects for Good Manufacturing Practice. The workflow that holds up is: build a longlist from the OneFirmIntel directory using tier, industry, and state filters, then verify each shortlisted name against ANVISA's public registration records before you engage. The register tells you the company exists and is solvent; ANVISA tells you it is licensed to make what you need.

On access, aggregate tier counts like the ones in this article are free to view. Individual company records, including identifiers and detail, are credit-gated. Free searches surface a capped set of top results per query, while paid plans unlock full pagination and export so you can pull the complete Established-tier list for outreach. The broader Brazil company directory lets you cross-reference adjacent sectors such as chemicals and wholesale, and the pharmaceuticals industry overview puts Brazil's manufacturer count in context against the other 23 markets we track.

Cross-Border Practical Notes

Three things trip up first-time buyers sourcing from Brazil. First, the company identifier. Every Brazilian legal entity has a CNPJ, the national registry number, and you should capture it early, because it is the key that links register data, tax status, and ANVISA records to one another. Second, regulatory registration is product-specific and time-bound. An ANVISA manufacturing licence is not the same as having a particular drug registered for sale, and registrations expire and must be renewed, so confirm the exact product and its current status rather than relying on the company licence alone. Third, language and documentation. Official records, contracts, and regulatory filings are in Portuguese, and technical or import documentation often needs certified translation, so build that into timelines. None of these are blockers, but each is easier to handle when you have verified the company against both the register and ANVISA before money or product moves.